Research Triangle Park, NC and Aurora, ON Canada - September 7, 2010 - Copernicus Group IRB (CGIRB), a leading independent institutional review board, today announced a new strategic alliance with IRB Services of Canada. This partnership will enable CGIRB to offer institutional review services to its clients whose clinical research protocols include Canadian sites. The objective of this alliance is to provide CGIRB clients a single solution for ethical review of clinical research protocols and sites in North America.
Each client will work with a dedicated CGIRB single point of contact with team support bridging both IRBs. The integrated team will ensure an expeditious and thorough ethical review and quality client service in full compliance with regulatory and ethical requirements in both countries.
“This alliance will benefit both organizations by providing a seamless service to CGIRB clients who plan to include Canadian sites in addition to US research,” said Jack Corman, CEO and Founder of IRB Services. “I am delighted to be partnering with Copernicus Group IRB, one of the leading independent IRBs in the United States.”
This new alliance, coupled with with CGIRB’s ISO 9001:2008 certification, AAHRPP accreditation, and existing corporate partnerships, will expand on CGIRB’s commitment to protect the rights and welfare of human subjects by providing innovative service offerings and quality review.
“We are pleased to provide this new offering to our clients who have requested additional service extending into Canada. It supports our dedication to superior quality and innovation,” said Bruce Tomason, CEO of CGIRB. “IRB Services is a highly regarded independent institutional review board with deep and insightful understanding of the Canadian research regulatory and ethical landscape nationally and in every province of the country. This alliance will further enhance our shared mission of human subject protection.”
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.